Year 2024 / Volume 116 / Number 12
Review
Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis

671-679

DOI: 10.17235/reed.2024.10053/2023

Zhaoxu Tian, Yonghua Chen, Yingxin Yao, Lihua Chen, Xiakai Zhu, Zhaocong Shen, Shanwei Yang, Hangbin Jin,

Abstract
Background: research on the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune hepatitis (AIH) has produced varied results, and the determinants of the immunological response remain largely elusive. Methods: a comprehensive search of three primary databases (PubMed, Embase, and Web of Science) yielded pertinent studies on the topic. The data extraction was a collaborative effort among three independent researchers, who subsequently reconvened to validate the key data that were collated. The primary outcomes were the magnitudes of humoral and cellular immune responses to the vaccines. The secondary outcomes were related to factors affecting the humoral immune response post-vaccination. Results: this systematic review incorporated eight studies, and the meta-analysis involved three studies. The average antibody response rates after one, two, and three doses of the SARS-CoV-2 vaccine were 86 %, 82 %, and 91 %, respectively. Unexpectedly, the antibody concentrations of seropositive patients were markedly lower than those of their healthy counterparts. The cellular immune response rates after two and three vaccine doses were 74 % and 56 %, respectively. Treatment with mycophenolate mofetil and corticosteroids was associated with a notable decrease in seropositivity (pooled odds ratio [95 % confidence interval]: 2.62 [2.12-3.25] and 2.4 [1.51-3.82], respectively). In contrast, azathioprine had no discernable impact on the humoral response. Conclusion: in patients with AIH, the immune response to COVID-19 vaccination is attenuated. Specific immunosuppressive agents, such as steroids and MMF, have been found to reduce antibody responses. Recognizing these determinants is crucial to formulating individualized vaccination strategies for patients with AIH. Further research with an emphasis on post-vaccination cellular immunity will be essential to refine the vaccination approaches for this demographic.
Share Button
New comment
Comments
No comments for this article
References
1. WHO. COVID-19 Epidemiological Update Edition 159. 09/09 2023;
2. Ge J, Pletcher MJ, Lai JC. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology. Nov 2021;161(5):1487-1501.e5. doi:10.1053/j.gastro.2021.07.010
3. Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology. Aug 2020;159(2):768-771.e3. doi:10.1053/j.gastro.2020.04.064
4. Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology (Baltimore, Md). Aug 2021;74(2):1049-1064. doi:10.1002/hep.31751
5. Marjot T, Eberhardt CS, Boettler T, et al. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of hepatology. Oct 2022;77(4):1161-1197. doi:10.1016/j.jhep.2022.07.008
6. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md). Aug 2020;72(2):671-722. doi:10.1002/hep.31065
7. Fishman JA. Opportunistic infections--coming to the limits of immunosuppression? Cold Spring Harbor perspectives in medicine. Oct 1 2013;3(10):a015669. doi:10.1101/cshperspect.a015669
8. Zecher BF, Buescher G, Willemse J, et al. Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. United European gastroenterology journal. Sep 2021;9(7):797-808. doi:10.1002/ueg2.12100
9. Efe C, Lammert C, Taşçılar K, et al. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver international : official journal of the International Association for the Study of the Liver. Mar 2022;42(3):607-614. doi:10.1111/liv.15121
10. Efe C, Taşçılar K, Gerussi A, et al. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of autoimmunity. Oct 2022;132:102906. doi:10.1016/j.jaut.2022.102906
11. Duengelhoef P, Hartl J, Rüther D, et al. SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European gastroenterology journal. Apr 2022;10(3):319-329. doi:10.1002/ueg2.12218
12. Hartl J, Rüther DF, Duengelhoef PM, et al. Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis. Liver international : official journal of the International Association for the Study of the Liver. Feb 2023;43(2):393-400. doi:10.1111/liv.15368
13. Jorgensen K, Chopra A, Sexton J, et al. Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study. Journal of hepatology. 2022;77:S309.
14. Schneider L, Schubert L, Winkler F, Munda P, Winkler S, Tobudic S. SARS-CoV-2 Vaccine Response in Patients With Autoimmune Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Sep 2022;20(9):2145-2147.e2. doi:10.1016/j.cgh.2022.04.006
15. Zhou H, Ye Q. Clinical Features of COVID-19 Vaccine-Associated Autoimmune Hepatitis: A Systematic Review. Diseases (Basel, Switzerland). May 30 2023;11(2)doi:10.3390/diseases11020080
16. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed). Jul 21 2016;354:i4086. doi:10.1136/bmj.i4086
17. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS medicine. Oct 2014;11(10):e1001744. doi:10.1371/journal.pmed.1001744
18. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000;
19. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 2008;
20. Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature medicine. Jul 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
21. Zecca E, Rizzi M, Tonello S, et al. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. Viruses. Aug 12 2022;14(8)doi:10.3390/v14081766
22. Chauhan M, Nzeako I, Li F, Thuluvath PJ. Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases. Annals of Hepatology. 2022;27(4):100702.
23. Moriya K, Nakakita T, Nakayama N, et al. SARS-CoV-2 Vaccination Response in Japanese Patients with Autoimmune Hepatitis: Results of Propensity Score-Matched Case–Control Study. Journal of Clinical Medicine. 2023;12(16):5411.
24. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. Journal of hepatology. Dec 2014;61(6):1385-96. doi:10.1016/j.jhep.2014.08.010
25. Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature communications. Jul 24 2020;11(1):3774. doi:10.1038/s41467-020-17703-6
26. Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012. e19.
27. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell reports. Feb 9 2021;34(6):108728. doi:10.1016/j.celrep.2021.108728
28. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, NY). Feb 5 2021;371(6529)doi:10.1126/science.abf4063
29. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature reviews Immunology. Aug 2021;21(8):475-484. doi:10.1038/s41577-021-00578-z
30. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature medicine. Jul 2021;27(7):1147-1148. doi:10.1038/s41591-021-01432-4
31. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. Morbidity and Mortality Weekly Report. 2021;70(34):1150.
32. Dimitriadis S, Meacham G, Irwin S, et al. Humoral and cellular immune responses to wild-type and omicron (B. 1.1. 529) SARS-CoV-2 variants following a fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis. Journal of hepatology. 2022;77:S58.
33. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis care & research. 2013;65(3):476-480.
34. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501. e15.
35. Duclos H, Maillot MC, Galanaud P. Differential effects of azathioprine on T cells regulating murine B-cell function. Immunology. Jul 1982;46(3):595-601.
36. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the rheumatic diseases. Oct 2021;80(10):1330-1338. doi:10.1136/annrheumdis-2021-220647
37. Benotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. Jun 2021;99(6):1498-1500. doi:10.1016/j.kint.2021.04.005
38. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. May 2000;47(2-3):85-118. doi:10.1016/s0162-3109(00)00188-0
39. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis & rheumatology (Hoboken, NJ). Jan 2023;75(1):E1-e16. doi:10.1002/art.42372
40. Trontzas IP, Kyriakoulis KG, Vathiotis IA, et al. Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines. 2022;10(12):2073.
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Citation tools
Tian Z, Chen Y, Yao Y, Chen L, Zhu X, Shen Z, et all. Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis. 10053/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 74 visits.
This article has been downloaded 9 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 31/10/2023

Accepted: 13/12/2023

Online First: 18/01/2024

Published: 13/12/2024

Article revision time: 35 days

Article Online First time: 79 days

Article editing time: 409 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology